BELGRADE, Mont. , Oct. 06, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, today provided an informational update to stockholders and convertible note

BELGRADE, Mont. , Oct. 06, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced the appointment of Carl O’Connell as President, reporting to the CEO effective October 6, 2016 . Mr.

BELGRADE, Mont. , Aug. 29, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, today announced it filed a registration statement on Form S-1 with the Securities

BELGRADE, Mont. , Aug. 19, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, today announced that the NYSE MKT LLC (the "Exchange") notified the Company that

Expanded credit facility to provide additional liquidity for future growth BELGRADE, Mont. , Aug. 16, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, today

*See footnote about the use of pro forma financial information Second Quarter 2016 Highlights: Core recurring revenue (excluding OEM and other revenue) increased 5.6% to $20.9 million compared to core pro forma recurring revenue of $19.8 million in second quarter 2015  Gross profit increased to

BELGRADE, Mont. , July 26, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced the expansion of its tissue processing facility in Belgrade, MT , which now includes an additional

Second Quarter 2016 Revenue in the range of $21.45 million to $21.65 million Core recurring revenue to increase 5.6% to 6.6% over the same period last year EBITDA projected to be $300,000-$400,000 for Second Quarter 2016 BELGRADE, Mont. , July 20, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings,

BELGRADE, Mont. , July 19, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that it will release its financial results for the period ended June 30th 2016, at the close of the

BELGRADE, Mont. , June 16, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced the appointment of Paul Buckman , Eric Timko , and Rudy Mazzocchi to its Board of Directors.  The